M/19/046 – Recipharm/Consort
The proposed acquisition whereby Recipharm Holdings Limited will acquire sole control of Consort Medical Plc has been cleared by the Competition and Consumer Protection Commission.
|Notification date||Decision date|
|Friday December 20, 2019||Tuesday, January 28, 2020|
|Parties Involved||Business activities|
|Recipharm Holdings Limited||
Recipharm Holdings Limited is a wholly owned subsidiary of the Recipharm Group.
Recipharm Group is a global contract development and manufacturing organisation (CDMO). It is a global provider of drug development and manufacturing services to the pharmaceutical industry.
Recipharm Group offers manufacturing services for finished dose pharmaceuticals (FDPs) and active pharmaceutical ingredients (APIs).
Recipharm Group has no manufacturing or development facilities in the State. However, it does have sales to pharmaceutical companies based in the State.
|Consort Medical Plc||
Consort is a global CDMO providing drug formulation and manufacture (both FDPs and APIs) as well as drug delivery device development and manufacture to pharmaceutical partners globally and in the State.
|Economic sector||Media merger|
|Submissions from third parties due by:|
|Phase 1||Phase 2|
|Tuesday, January 7, 2020|
|Current status: Completed|
|Cleared (Phase 1)|
|Authorised Officer Assigned||Contact Details|
Media enquiries: email@example.com